Abstract
Get full access to this article
View all access options for this article.
References
1.
Philippidis
A
. Astellas Dyno Launch Up-to-$1.6B+ Gene Therapy Collaboration. Genetic Engineering & Biotechnology News. December 1, 2021. https://www.genengnews.com/topics/genome-editing/gene-therapy/astellas-dyno-launch-up-to-1-6b-gene-therapy-collaboration/ (last accessed
December 5 , 2021
).
2.
Astellas Pharma and Dyno Therapeutics. Astellas and Dyno Therapeutics Announce Research Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Skeletal and Cardiac Muscle. December 1, 2021. https://www.dynotx.com/astellas-and-dyno-therapeutics-announce-research-collaboration-to-develop-next-generation-aav-gene-therapy-vectors-for-skeletal-and-cardiac-muscle/ (last accessed
December 5 , 2021
).
3.
FUJIFILM Diosynth Biotechnologies. FUJIFILM Diosynth Biotechnologies confirms £400 million investment plans to create the largest multi-modal biopharmaceutical manufacturing site in the United Kingdom. December 2, 2021. https://fujifilmdiosynth.com/about-us/press-releases/fujifilm-diosynth-biotechnologies-confirms-400-million-investment-plans-to-create-the-largest-multi-modal-biopharmaceutical-manufacturing-site-in-the-united-kingdom/ (last accessed
December 14 , 2021
).
4.
AviadoBio. AviadoBio™ Raises $80 million in Series A Financing to Advance Neurodegenerative Gene Therapy Platform. December 2, 2021. https://aviadobio.com/aviadobio-raises-80-million-in-series-a-financing-to-advance-neurodegenerative-gene-therapy-platform/ (last accessed
December 5 , 2021
)
5.
Pfizer. Pfizer Invests $68.5 Million in New State-of-the-Art Facility in Durham, North Carolina to Further Advance Gene Therapy Capabilities. December 15, 2021. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invests-685-million-new-state-art-facility-durham (last accessed
December 15 , 2021
).
6.
Bluebird Bio. New and Updated Data Demonstrating Sustained Treatment Response in Patients Treated in Largest Sickle Cell Gene Therapy Program To-Date Presented at ASH21 and Published in NEJM. December 12, 2021. https://investor.bluebirdbio.com/news-releases/news-release-details/new-and-updated-data-demonstrating-sustained-treatment-response (last accessed
December 14 , 2021
).
7.
TATAA Biocenter. TATAA Biocenter Announces the Opening of New GLP Compliant Laboratory in Gothenburg, Sweden. December 2, 2021. https://www.mynewsdesk.com/se/tataa-biocenter-ab/pressreleases/tataa-biocenter-announces-the-opening-of-new-glp-compliant-laboratory-in-gothenburg-sweden-3148150 (last accessed
December 14 , 2021
).
8.
Intellia Therapeutics. Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema. December 13, 2021. https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-first-patient-dosed-phase-12 (last accessed
December 5 , 2021
).
9.
Spark Therapeutics. Spark Therapeutics Updated SPK-8011 Data from Phase 1/2 Study Shows Multi-Year, Durable Factor VIII (FVIII) Expression that Significantly Reduced Bleeding in Hemophilia A Patients. November 17, 2021. https://sparktx.com/press_releases/spark-therapeutics-updated-spk-8011-data-from-phase-1-2-study-shows-multi-year-durable-factor-viii-fviii-expression-that-significantly-reduced-bleeding-in-hemophilia-a-patients/ (last accessed
December 5 , 2021
).